As a new-type foreign trade service provider driven by both technology transformation and foreign trade services, HiSiaddi has established a service system of "1+2+3+4=1", which can supply original-source Ticagrelor advanced intermediates from multiple well-known brands.
As a R&D-oriented foreign trade service provider, HiSiaddi has conducted multiple rounds of factory audits for Ticagrelor advanced intermediate manufacturers through technological transformation cooperation with manufacturers, accumulating objective and in-depth understanding of different brands. We regularly analyze domestic Ticagrelor intermediate manufacturers for clients to help them select matching products. Below is the brand recommendation case.
If you require further comparative analysis of brands and product models, please contact HiSiaddi customer service.
The client is Gulf Pharma LLC, a high-end pharmaceutical group headquartered in Dubai, UAE, specializing in R&D and production of novel cardiovascular and metabolic drugs and high-end generics. Its products cover high-end medical markets across the Middle East, North Africa and Western Europe, fully complying with FDA, EMA and ICH Q7 quality standards. Its core products are high-purity Ticagrelor API and long-acting sustained-release formulations, with an annual procurement volume of 300 kg for Ticagrelor advanced intermediates. The client imposes stringent requirements on chiral purity, impurity control, batch stability and compliance certifications, representing a typical mid-to-high-end customer.
Client Pain Points: This is the client’s first procurement of advanced intermediates from China, lacking systematic knowledge of leading domestic manufacturers, technical capabilities, mainstream product models and quality disparities. After contacting 5 manufacturers, each brand only promoted its own products while avoiding disclosure of competitors’ strengths, merely claiming "GMP-compliant with ≥99% purity" without objective comparison of technical capabilities, quality control levels and applicable scenarios. The client was unable to determine which brand/model aligns with its high-end formulation requirements, fearing that incorrect selection would trigger API quality non-compliance, delayed pharmaceutical registration and audit risks. The client entrusted HiSiaddi with full-dimensional brand analysis, objective comparison and targeted recommendations to ensure procurement of the most compatible mid-to-high-end products.
Based on industry databases, factory audit reports, product test data and feedback from overseas clients, HiSiaddi screened 5 technically leading manufacturers with GMP/COS certifications and proven service records for high-end pharmaceutical enterprises. An unbiased, comprehensive analysis was conducted across five dimensions: technical strength, mainstream models, core strengths, weaknesses and applicable scenarios.
Brand Positioning: Domestic leader in high-end chiral intermediates, specializing in high-end intermediates including Ticagrelor and anti-hepatitis C drug intermediates with EU COS certification, supplying global giants including Novartis and Sanofi. Mainstream Models:
· Model T-01: Ticagrelor Intermediate II (CAS: 376608-71-8), chiral purity ≥99.9%, single impurity ≤0.03%, GMP grade
· Model T-03: Ticagrelor Intermediate III (CAS: 376608-65-0), purity ≥99.5%, heavy metals <5 ppm, pharmaceutical grade Core Strengths: Globally top-tier chiral synthesis technology, extreme impurity control, robust batch-to-batch stability, highest recognition among high-end European and American pharmaceutical enterprises, full set of EMA/FDA compliance documents available. Weaknesses: Relatively high pricing, longer lead time (4–6 weeks). Applicable Scenarios: High-end sustained-release formulations, reference-listed drug registration, EMA/FDA audit projects.
Brand Positioning: Specialized chiral intermediate manufacturer, Henan Provincial Engineering Technology Research Center, with 15 years of deep engagement in Ticagrelor intermediates and a core supplier for the domestic mid-to-high-end market. Mainstream Models:
· Model K-02: Ticagrelor Intermediate II (CAS: 145783-15-9), chiral purity ≥99.8%, total impurity ≤0.1%, GMP grade
· Model K-03: Ticagrelor Intermediate III (CAS: 376608-65-0), purity ≥99.2%, stable crystal form, bulk production grade Core Strengths: Optimal cost-performance ratio, mature chiral technology, compliant impurity control, fast lead time (2–3 weeks), efficient service response. Weaknesses: Slightly limited high-end customization capacity; additional optimization required for certain extreme impurity indicators (e.g. genotoxic impurities). Applicable Scenarios: High-end generics, consistency evaluation projects, cost-sensitive mid-to-high-end clients.
Brand Positioning: Comprehensive cardiovascular intermediate service provider covering Ticagrelor, Rivaroxaban and other products with large production capacity and stable quality, leading the mid-tier market. Mainstream Models:
· Model Y-01: Ticagrelor Intermediate I (CAS: 145783-15-9), purity ≥99.0%, chiral purity ≥99.5%, industrial grade
· Model Y-03: Ticagrelor Intermediate III (CAS: 376608-65-0), purity ≥98.5%, low pricing, basic pharmaceutical grade Core Strengths: Large production capacity, low pricing, ultra-fast lead time (1–2 weeks), stable conventional quality suitable for mass production. Weaknesses: Inferior chiral purity and impurity control compared to Hongbo and Kexin; no COS certification, unable to support EMA/FDA audits. Applicable Scenarios: Conventional generics, non-audit projects, cost-prioritized clients.
Brand Positioning: Emerging high-end chiral enterprise with a new GMP facility commissioned in 2023, focusing on high-difficulty chiral intermediates with rapidly advancing technical capabilities. Mainstream Models:
· Model H-02: Ticagrelor Intermediate II, chiral purity ≥99.85%, single impurity ≤0.04%, GMP grade
· Model H-03: Ticagrelor Intermediate III, purity ≥99.3%, compliant residual solvents, pharmaceutical grade Core Strengths: New technology and advanced equipment, impurity control close to Hongbo’s standards, pricing 10%–15% lower than Hongbo, flexible customization. Weaknesses: Short operational history with limited overseas high-end client validation records; mass production stability yet to be fully verified. Applicable Scenarios: Mid-to-high-end generics, emerging pharmaceutical enterprises, clients pursuing premium quality at competitive costs.
Brand Positioning: Backbone intermediate manufacturer in Southwest China, specializing in Ticagrelor and anticoagulant intermediates with high regional market share. Mainstream Models:
· Model R-03: Ticagrelor Intermediate III (CAS: 376608-65-0), purity ≥99.0%, water content ≤0.1%, basic pharmaceutical grade Core Strengths: Strong regional customer service, moderate pricing, stable lead time, reliable conventional quality. Weaknesses: No proprietary chiral synthesis technology, reliant on outsourced chiral raw materials; no high-end product models available, incomplete compliance documentation. Applicable Scenarios: Domestic generics, regional market supply, non-high-end audit projects.
Combining the client’s core demands for high-end sustained-release formulations, EMA audit compliance, extreme impurity control, 300kg annual procurement volume and balanced quality-cost priorities, HiSiaddi conducted objective screening and recommended 2 mid-to-high-end manufacturers and 3 core models with clear rationale, compatibility analysis and risk disclosures for client decision-making.
Recommended Model 1: T-01 (Ticagrelor Intermediate II, CAS: 376608-71-8) Core Specifications: Chiral purity ≥99.9%, single impurity ≤0.03%, total impurity ≤0.1%, heavy metals <5 ppm Recommendation Rationale: Globally leading chiral purity and impurity control fully align with the client’s stringent sustained-release formulation requirements. Full set of EMA compliance documents plus validation records from international pharmaceutical giants enable one-time audit clearance. Sufficient annual production capacity supports 300kg procurement volume. Applicable Scenarios: Core API synthesis, EMA/FDA audits, long-term stable supply.
Recommended Model 2: K-02 (Ticagrelor Intermediate II, CAS: 145783-15-9) Core Specifications: Chiral purity ≥99.8%, single impurity ≤0.05%, total impurity ≤0.1% Recommendation Rationale: Quality nearly equivalent to Hongbo’s products with 20%–25% lower pricing for optimal cost-performance ratio. Mature chiral technology delivers compliant impurity control meeting basic EMA audit standards, supported by fast 2–3 week lead time and responsive service with flexible capacity adjustment. Applicable Scenarios: Auxiliary API synthesis, consistency evaluation projects, cost optimization workflows.
Recommended Model 3: K-03 (Ticagrelor Intermediate III, CAS: 376608-65-0) Core Specifications: Purity ≥99.2%, stable crystal form, residual solvents ≤500 ppm Recommendation Rationale: Core raw material for Intermediate III with stable quality and moderate pricing. High process compatibility with Model K-02 reduces overall procurement costs via bundled purchasing. Minimal batch-to-batch physical property variation adapts to the client’s continuous-flow production line. Applicable Scenarios: Ticagrelor Intermediate III synthesis, bundled procurement, continuous mass production.
1. Changzhou Yuanda: Substandard chiral purity and impurity control, no COS certification, unable to pass EMA audits.
2. Zhuhai Hairui De: Limited overseas validation records and unproven mass production stability carry elevated operational risks.
3. Chongqing Ruibolai: Lack of proprietary chiral synthesis technology, no high-end product portfolio and incomplete compliance documentation.
HiSiaddi coordinated sample provision: 500g Model T-01 from Hongbo Zhiyuan, 500g each of Model K-02 and K-03 from Xinxiang Kexin, accompanied by English COA, chromatograms and full compliance documents. HiSiaddi assisted the client with sample testing, lab-scale compatibility trials and impurity comparison. Test results confirmed Model T-01 fully meets high-end formulation standards while K-02/K-03 satisfy auxiliary production requirements with zero quality deviations.
Based on the client’s 300kg annual procurement volume, HiSiaddi negotiated exclusive pricing, lead time guarantees, quality compensation clauses and technical support terms with both manufacturers:
1. Hongbo Zhiyuan: 8% discount on Model T-01, fixed 4-week lead time per batch, complimentary technical support and full audit coordination.
2. Xinxiang Kexin: 12% discount on Model K-02/K-03, fixed 3-week lead time per batch, unconditional return & exchange for non-compliant products.
The client ultimately signed a dual-brand procurement contract: 60% of annual volume (180kg) sourced from Hongbo T-01 and 40% (120kg) from Xinxiang Kexin K-02/K-03, balancing premium quality, cost control and supply chain resilience.
The first shipment (30kg Hongbo T-01; 20kg Xinxiang K-02; 20kg Xinxiang K-03) arrived on schedule with client testing results as follows:
· Hongbo T-01: Chiral purity 99.93%, single impurity 0.02%, total impurity 0.07%, exceeding all specifications
· Xinxiang K-02: Chiral purity 99.82%, single impurity 0.04%; K-03: Purity 99.3%, stable crystal form, fully compliant All products passed client quality acceptance and EMA pre-audit without objections.
Client Comment from Procurement Director: “HiSiaddi acts as a truly neutral and professional partner, avoiding biased promotion of any single brand while objectively analyzing strengths and weaknesses to deliver recommendations precisely aligned with our high-end requirements. The Hongbo and Kexin products we sourced satisfy both EMA audit’s extreme quality benchmarks and cost control targets, completely resolving our pain point of limited understanding of Chinese manufacturers, far exceeding our expectations.”
Long-Term Cooperation Arrangement The client entrusted HiSiaddi with brand selection and procurement for all Ticagrelor series intermediates and intermediates for 2 follow-up novel anticoagulant drugs under research, establishing a long-term strategic partnership.
Core Case Value Overseas mid-to-high-end clients purchasing Chinese pharmaceutical intermediates face core pain points including asymmetric brand information, biased self-promotion by manufacturers and inability to conduct objective comparative selection. HiSiaddi’s core value lies in its third-party neutral perspective, full-dimensional factory research, transparent objective comparison and targeted demand-aligned recommendations. Rather than aggressive product sales, HiSiaddi delivers optimal solutions solely based on client technical and compliance requirements, helping clients mitigate quality and compliance risks from incorrect brand selection while balancing quality and cost. This fully embodies the core value of professional foreign trade service providers: objectivity, professionalism and client empowerment.
If you require further comparative analysis of brands and product models, please contact HiSiaddi customer service.
+86-13120989737 
info@hisiaddi.com 
English
